About Owkin
Owkin is a company based in Paris (France) founded in 2016 by Gilles Wainrib and Thomas Clozel. It operates as a AI-as-a-Service, Professional Services, and HealthTech. Owkin has raised $354.1 million across 13 funding rounds from investors including Sanofi, Mubadala and Plug and Play Tech Center. Owkin offers products and services including Owkin K Pro, Owkin K Navigator, MSIntuit® CRC, and RlapsRisk® BC. Owkin operates in a competitive market with competitors including Formation Bio, BigHat, Benchsci, Predictive Oncology and Iambic Therapeutics, among others.
- Headquarter Paris, France
- Founders Gilles Wainrib, Thomas Clozel
- Stage Unicorn
-
Sectors
TechnologyHealthcare
-
Email
Locked
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Owkin, Inc
-
Annual Revenue
Not available
-
Net Profit
Not available
-
EBITDA
Not available
-
Total Equity Funding
$354.1 M (USD)
in 13 rounds
-
Latest Funding Round
$33 M (USD), Series B
Mar 12, 2026
-
Investors
Sanofi
& 20 more
-
Employee Count
Not available
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of Owkin
Owkin offers a comprehensive portfolio of products and services, including Owkin K Pro, Owkin K Navigator, MSIntuit® CRC, and RlapsRisk® BC.
Agentic AI tool for biopharma decision-making support.
AI co-pilot for biomedical research and exploration.
AI tool for optimizing colorectal cancer MSI testing.
AI assesses relapse risk in early breast cancer.
People of Owkin
Unlock access to complete
Unlock access to complete
Leadership Team
25 people
Senior Team
16 people
Software Development Team
14 people
Sales and Marketing
12 people
Human Resources and Administration
11 people
Scientific Team
9 people
Operations Team
9 people
Product Management Team
8 people
Unlock access to complete
Funding Insights of Owkin
Owkin has successfully raised a total of $354.1M across 13 strategic funding rounds. The most recent funding activity was a Series B round of $33 million completed in March 2026. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in Owkin
Owkin has secured backing from 21 investors, including institutional, venture fund, and angel investors. Prominent investors backing the company include Sanofi, Mubadala and Plug and Play Tech Center.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Venture capital investments are made in technology startups through a global ecosystem.
|
Locked | Locked | Locked | |
|
Corporate backed venture capital fund investing in multiple sectors
|
Locked | Locked | Locked | |
|
Investments in life sciences, technology, healthtech, and crypto sectors from global locations.
|
Locked | Locked | Locked |
Investor details for Owkin
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Owkin
Investment portfolio details for Owkin
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - Owkin
Detailed financials for Owkin
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Owkin Comparisons
Peer comparison for Owkin
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Owkin
Owkin operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Formation Bio, BigHat, Benchsci, Predictive Oncology and Iambic Therapeutics, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
AI-powered drug discovery platform for various diseases
|
|
| Locked | Locked | Locked |
Antibody therapies are developed through machine learning and synthetic biology.
|
|
| Locked | Locked | Locked |
AI platform used for extracting antibody data from scientific papers.
|
|
| Locked | Locked | Locked |
AI-based platform for cancer diagnostics and precision medicine is utilized.
|
|
| Locked | Locked | Locked |
AI-driven drug discovery platform for the treatment of cancer
|
Detailed competitors of Owkin
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Owkin
Complete news archive for Owkin
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Owkin
Owkin was founded in 2016.
Owkin is headquartered in Paris, France.
Thomas Clozel is the current CEO of Owkin. They have also founded this company.
Owkin is a funded company, having raised a total of $354.1M across 13 funding rounds to date.
Owkin is engaged in transforming healthcare by leveraging agentic AI to understand complex biology. The company is involved in drug discovery, development, and diagnostics within the biopharma and healthcare sectors. Solutions are developed to process vast biological data, uncover hidden relationships, and generate actionable insights. Multimodal patient data is accessed from diverse populations through partnerships with top academic institutions. Owkin K, an AI platform, is utilized to drive decision-making and accelerate breakthroughs across various teams. Additionally, diagnostic tools are provided for precision pathology in oncology, supporting clinical trials and routine clinical use.
Owkin's top competitors include Formation Bio, XtalPi and Benchsci.
Owkin offers Owkin K Pro, Owkin K Navigator, MSIntuit® CRC, and RlapsRisk® BC.
Owkin has 21 investors. Key investors include Sanofi, Mubadala, Plug and Play Tech Center, Bpifrance, and European Union.
The valuation of Owkin is $1B as of Nov 2021.